Coronavirus and Atopic Dermatitis (AD) / Alopecia Reporting Database
Given the interest in the emerging and evolving coronavirus (COVID-19) pandemic and the questions regarding how this will impact patients with atopic dermatitis (AD) or alopecia who are treated with or without systemic immunomodulating medication, we have created a number of secure, online, de-identified Personal Health Identifier (PHI) – free reporting registries and an anonymous patient reported survey.
We encourage clinicians worldwide to report ALL cases of COVID-19 in their alopecia and atopic dermatitis patients treated with or without systemic immunomodulating medication, regardless of severity (including asymptomatic patients detected through public health screening). Please follow the links below to register by clicking on either of the physician entered registry logos.
If you are a patient with atopic dermatitis and have developed COVID-19 we encourage you to complete the anonymous survey by clicking on the green SECURE-AD Patients survey logo.
Thank you in advance for your participation.
Atopic Dermatitis and COVID-19: Lessons from the SECURE-AD registry and beyond
A presentation held by Prof. Carsten Flohr MD PhD for the International Society of Atopic Dermatitis (ISAD) 2020 online meeting on September 3rd.